Skip to content
Triangle logo TriangleGet started
← Full study record

NCT04105010 · OUTCOME

Part A and Part B: Number of Participants With Adverse Events

Assessing An Oral Janus Kinase Inhibitor, AZD4205 as Monotherapy in Patients Who Have PTCL (JACKPOT8) · Source last updated 2025-04-04

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
COUNT_OF_PARTICIPANTS
Unit
Participants
Interval / dispersion
Not reported
Time frame
The first dose until 28 days after last dose, up to approximately 3 years

What was measured

To evaluate the safety and tolerability of AZD4205 in patients with PTCL in terms of adverse events (AEs), such as number of participants with AEs

Groups in this outcome

AZD4205 Group A

Group A: Open label AZD4205 at 150 mg, once daily (Phase 1) AZD4205: AZD4205 will be administered orally as capsules. AZD4205 treatment will be continued until disease progression or intolerant adverse reactions

AZD4205 Group B

Group B: Open label AZD4205 at 250 mg, once daily (Phase 1) AZD4205: AZD4205 will be administered orally as capsules. AZD4205 treatment will be continued until disease progression or intolerant adverse reactions

AZD4205 Group C

Group C: Open label AZD4205 at 150 mg, once daily (Phase 1) AZD4205: AZD4205 will be administered orally as capsules. AZD4205 treatment will be continued until disease progression or intolerant adverse reactions

AZD4205 Group D

Group D: Open label AZD4205 at the RP2D, once daily (Phase 2) AZD4205: AZD4205 will be administered orally as capsules. AZD4205 treatment will be continued until disease progression or intolerant adverse reactions

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
AZD4205 Group A28
AZD4205 Group B16
AZD4205 Group C7
AZD4205 Group D120

Reported measurements

Source class 1
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
AZD4205 Group A26Not reportedNot reportedNot reportedNot reported
AZD4205 Group B16Not reportedNot reportedNot reportedNot reported
AZD4205 Group C6Not reportedNot reportedNot reportedNot reported
AZD4205 Group D115Not reportedNot reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        26
      2. group Id
        OG001
        value
        16
      3. group Id
        OG002
        value
        6
      4. group Id
        OG003
        value
        115
denoms
  1. counts
    1. group Id
      OG000
      value
      28
    2. group Id
      OG001
      value
      16
    3. group Id
      OG002
      value
      7
    4. group Id
      OG003
      value
      120
    units
    Participants
description
To evaluate the safety and tolerability of AZD4205 in patients with PTCL in terms of adverse events (AEs), such as number of participants with AEs
groups
  1. description
    Group A: Open label AZD4205 at 150 mg, once daily (Phase 1) AZD4205: AZD4205 will be administered orally as capsules. AZD4205 treatment will be continued until disease progression or intolerant adverse reactions
    id
    OG000
    title
    AZD4205 Group A
  2. description
    Group B: Open label AZD4205 at 250 mg, once daily (Phase 1) AZD4205: AZD4205 will be administered orally as capsules. AZD4205 treatment will be continued until disease progression or intolerant adverse reactions
    id
    OG001
    title
    AZD4205 Group B
  3. description
    Group C: Open label AZD4205 at 150 mg, once daily (Phase 1) AZD4205: AZD4205 will be administered orally as capsules. AZD4205 treatment will be continued until disease progression or intolerant adverse reactions
    id
    OG002
    title
    AZD4205 Group C
  4. description
    Group D: Open label AZD4205 at the RP2D, once daily (Phase 2) AZD4205: AZD4205 will be administered orally as capsules. AZD4205 treatment will be continued until disease progression or intolerant adverse reactions
    id
    OG003
    title
    AZD4205 Group D
param Type
COUNT_OF_PARTICIPANTS
reporting Status
POSTED
time Frame
The first dose until 28 days after last dose, up to approximately 3 years
title
Part A and Part B: Number of Participants With Adverse Events
type
SECONDARY
unit Of Measure
Participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice